1. Home
  2. DAWN vs PAVS Comparison

DAWN vs PAVS Comparison

Compare DAWN & PAVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DAWN
  • PAVS
  • Stock Information
  • Founded
  • DAWN 2018
  • PAVS 2004
  • Country
  • DAWN United States
  • PAVS United States
  • Employees
  • DAWN N/A
  • PAVS N/A
  • Industry
  • DAWN Biotechnology: Pharmaceutical Preparations
  • PAVS Medicinal Chemicals and Botanical Products
  • Sector
  • DAWN Health Care
  • PAVS Health Care
  • Exchange
  • DAWN Nasdaq
  • PAVS Nasdaq
  • Market Cap
  • DAWN 1.3B
  • PAVS 61.9M
  • IPO Year
  • DAWN 2021
  • PAVS 2019
  • Fundamental
  • Price
  • DAWN $12.79
  • PAVS $1.36
  • Analyst Decision
  • DAWN Strong Buy
  • PAVS
  • Analyst Count
  • DAWN 7
  • PAVS 0
  • Target Price
  • DAWN $36.17
  • PAVS N/A
  • AVG Volume (30 Days)
  • DAWN 937.9K
  • PAVS 58.0K
  • Earning Date
  • DAWN 10-30-2024
  • PAVS 01-09-2025
  • Dividend Yield
  • DAWN N/A
  • PAVS N/A
  • EPS Growth
  • DAWN N/A
  • PAVS N/A
  • EPS
  • DAWN N/A
  • PAVS N/A
  • Revenue
  • DAWN $101,953,000.00
  • PAVS $6,544,819.00
  • Revenue This Year
  • DAWN N/A
  • PAVS N/A
  • Revenue Next Year
  • DAWN $36.10
  • PAVS N/A
  • P/E Ratio
  • DAWN N/A
  • PAVS N/A
  • Revenue Growth
  • DAWN N/A
  • PAVS N/A
  • 52 Week Low
  • DAWN $11.94
  • PAVS $0.32
  • 52 Week High
  • DAWN $18.07
  • PAVS $2.97
  • Technical
  • Relative Strength Index (RSI)
  • DAWN 39.97
  • PAVS 75.67
  • Support Level
  • DAWN $12.26
  • PAVS $1.03
  • Resistance Level
  • DAWN $12.81
  • PAVS $1.45
  • Average True Range (ATR)
  • DAWN 0.52
  • PAVS 0.10
  • MACD
  • DAWN -0.05
  • PAVS 0.05
  • Stochastic Oscillator
  • DAWN 28.94
  • PAVS 83.32

About DAWN Day One Biopharmaceuticals Inc.

Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor.

About PAVS Paranovus Entertainment Technology Ltd.

Paranovus Entertainment Technology Ltd through its subsidiary, is engaged in the AI-powered entertainment industry, aiming to provide users with AI-driven games and applications to deliver immersive and engaging entertainment experiences. It is planning to launch SimTwin application which will allow users to interact with digital versions of people and capture life moments. The company also has a software development agreement with Blueline Studios Inc which is developing 10,000 Lives, a mobile game where players pursue various careers and life goals using a board game mechanic.

Share on Social Networks: